Your browser doesn't support javascript.
loading
Efficacy of probiotics/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Liu, Chang; Yang, Letian; Wei, Wei; Fu, Ping.
Afiliación
  • Liu C; Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu, China.
  • Yang L; Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu, China.
  • Wei W; Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu, China.
  • Fu P; Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu, China.
Front Nutr ; 11: 1434613, 2024.
Article en En | MEDLINE | ID: mdl-39166132
ABSTRACT

Background:

Chronic kidney disease (CKD) is a serious and steadily growing health problem worldwide. Probiotic and synbiotic supplementation are expected to improve kidney function in CKD patients by altering imbalanced intestinal flora, regulating microbiota metabolites, modulating the brain-gut axis, and reducing inflammation.

Objectives:

Our aim is to report the latest and largest pooled analyses and evidence updates to explore whether probiotic and synbiotic have beneficial effects on renal function and general conditions in patients with CKD.

Methods:

We conducted a systematic literature search using PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials from inception until 1 December 2023. Eligible literatures were screened according to inclusion and exclusion criteria, data were extracted, and a systematic review and meta-analysis was performed. Measurements included renal function-related markers, inflammatory markers, uremic toxins, lipid metabolism-related markers and electrolytes levels.

Results:

Twenty-one studies were included. The results showed that probiotic/synbiotic significantly reduced blood urea nitrogen (BUN) (standardized mean difference (SMD), -0.23, 95% confidence interval (CI) -0.41, -0.04; p = 0.02, I2 = 10%) and lowered c-reactive protein level (CRP) (SMD -0.34; 95% CI -0.62, -0.07; p = 0.01, I2 = 37%) in CKD patients, compared with the control group.

Conclusion:

In summary, probiotic/synbiotic supplementation seems to be effective in improving renal function indices and inflammation indices in CKD patients. Subgroup analyses suggested that longer-term supplementation is more favorable for CKD patients, but there is a high degree of heterogeneity in the results of partial subgroup analyses. The efficacy of probiotic/synbiotic in treating CKD needs to be supported by more evidence from large-scale clinical studies. Systematic review registration https//www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024526836, Unique identifier CRD42024526836.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Nutr Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Nutr Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza